Shuttle Pharmaceuticals Reports Q3 2025 Financial Results with Improved Net Loss

Shuttle Pharmaceuticals Holdings, Inc. reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a net loss of $2.35 million for the quarter, a 38% improvement from a net loss of $3.78 million in the same period last year. For the nine-month period, the company recorded a net loss of $9.11 million, compared to a loss of $7.55 million in the prior year. The company did not generate any revenue during these periods, maintaining a consistent trend from previous quarters.

Operating expenses for the third quarter totaled $2.27 million, down 26% from $3.05 million in the prior year. This decrease was primarily driven by a reduction in research and development (R&D) expenses, which fell to $943,478 from $1.40 million, reflecting a strategic shift in spending. General and administrative expenses, however, surged by 169% to $886,055, largely due to increased costs associated with investor relations. Legal and professional fees also decreased significantly, dropping 67% to $437,409, as the company incurred higher expenses in the previous year related to financial statement restatements.

In terms of financial position, Shuttle Pharmaceuticals reported total current assets of $3.27 million as of September 30, 2025, a 48% increase from $2.21 million at the end of 2024. This growth was primarily attributed to cash and cash equivalents, which rose to $2.09 million from $1.92 million. Current liabilities also increased by 28% to $1.96 million, resulting in working capital of approximately $1.30 million, a 92% increase from the previous year. The company’s financial health is further supported by recent equity raises, including a $5 million net cash infusion from a March 2025 public offering and $3.9 million from a June 2025 private placement.

Strategically, the company is advancing its clinical development of Ropidoxuridine, a drug designed to sensitize cancer cells to radiation therapy. The company has initiated a Phase II clinical trial, following FDA recommendations to expand the study. However, the termination of a master agreement with its primary contract research organization, Theradex Systems, Inc., raises concerns about the continuity and timing of clinical trials. In response, Shuttle Pharmaceuticals is exploring alternative options to mitigate potential impacts on its development plans.

Looking ahead, the company faces significant challenges, including the need for additional financing to support ongoing operations and clinical trials. The recent issuance of a securities purchase agreement for a private placement transaction is expected to provide approximately $2.5 million in gross proceeds. However, the company has acknowledged substantial doubt about its ability to continue as a going concern within the next year, emphasizing the critical need for effective capital management and strategic partnerships to ensure its long-term viability.